Cite this answer
Retinalamin: quick citable summary
Retinalamin is listed by PeptaHub as a other peptide with a research only legal-status classification. The page summarizes mechanism, research context, common routes, safety notes, and references for writers and AI answer engines.
PeptaHub. “Retinalamin: Mechanism, Research Context, Safety.” peptahub.com, 2026. https://peptahub.com/peptides/retinalamin. Licensed CC BY 4.0.
License: Creative Commons Attribution 4.0 International. Link back to https://peptahub.com/peptides/retinalamin.
What is Retinalamin?
Retinalamin is a bovine retinal polypeptide registered in Russia for AMD, retinitis pigmentosa, and diabetic retinopathy. Russian observational series report visual improvement in roughly 50-80% of patients; no RCTs have been completed.
Overview
Retinalamin is a polypeptide preparation isolated from bovine retinal tissue, developed by Professor Vladimir Khavinson and registered as a pharmaceutical drug in Russia for the treatment of retinal degenerative diseases. It is studied for age-related macular degeneration (AMD), retinitis pigmentosa, and diabetic retinopathy, and is the primary ocular bioregulator in the Khavinson peptide system.
Mechanism of action
Retinalamin is a complex of water-soluble polypeptide fractions with molecular weight below 10,000 Da, isolated from bovine retina by Khavinson's extraction method. It activates ocular tissue metabolism, normalizes cellular membrane function, improves intracellular protein synthesis, and regulates lipid peroxide oxidation in photoreceptor and pigment epithelial cells. By improving the functional interaction between the retinal pigment epithelium (RPE) and the outer segments of visual photoreceptors, it helps restore phototransduction efficiency. It also normalizes retinal vascular permeability, reducing macular edema. The preparation penetrates retinal layers after intramuscular injection, exerting tissue-specific bioregulatory effects on photoreceptor renewal and RPE metabolic activity.
Reported study ranges
| Purpose | Route | Reported range | Frequency | Notes |
|---|---|---|---|---|
| retinal degeneration research | intramuscular | 5–10 mg | daily for 10 days | Standard Russian clinical protocol: 5–10 mg IM daily for 10 days, repeated 2–3 times per year. Dissolve in 1–2 mL sterile saline. |
Reported ranges are for research context only. Consult a qualified healthcare professional before using any peptide.
Convert Retinalamin research-range units
Need to convert mg to mcg, dose volume, or U-100 syringe units? Use the peptide dose unit converter for educational calculation support.
Research summary
Russian observational clinical studies involving Retinalamin in AMD, retinitis pigmentosa, and diabetic retinopathy report visual function improvement in approximately 50-80% of treated patients, without randomized controlled trials to confirm these findings. A study combining Retinalamin with Epithalamin and Cortexin in 104 diabetic retinopathy patients showed improved visual acuity and reduced macular edema. Long-term outcome data in retinal degenerative disorders is published in Russian ophthalmology journals. No randomized controlled trials meeting FDA standards have been published in Western peer-reviewed literature. Retinalamin is registered and approved in Russia as a retinoprotective pharmaceutical.[1][2][3][4]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Retinalamin for synergistic effects.
Legal status
Registered pharmaceutical in Russia for retinal degenerative diseases. Not FDA-approved. Available in Western markets as a research chemical only. Cannot be sold or prescribed for therapeutic purposes in the US or EU.
Sourcing & access
Research compound
Retinalamin is classified as a research compound. Regulatory status varies by jurisdiction. Always verify current legal status and source from vendors providing third-party certificates of analysis (COA).
Frequently asked questions
Retinalamin is a polypeptide preparation isolated from bovine retinal tissue, developed by Professor Khavinson and registered as a pharmaceutical drug in Russia. It is the primary ocular bioregulator in the Khavinson peptide system, used for age-related macular degeneration, retinitis pigmentosa, and diabetic retinopathy.
Retinalamin contains water-soluble polypeptide fractions (under 10,000 Da) that activate ocular tissue metabolism, improve protein synthesis in photoreceptor and pigment epithelial cells, and normalize retinal vascular permeability. It improves the functional interaction between the retinal pigment epithelium and photoreceptor outer segments.
Reported side effects include injection site pain and rare transient visual disturbances. The long-term safety profile is not well characterized in Western literature. It is a registered pharmaceutical in Russia but is not FDA-approved and is available in Western markets only as a research substance.
Russian observational clinical studies report visual function improvement in approximately 50-80% of treated patients across series for AMD, retinitis pigmentosa, and diabetic retinopathy, without randomized controlled trials to confirm these findings. A combined retinalamin-epithalamin-cortexin study in 104 diabetic retinopathy patients showed improved visual acuity. No Western RCTs exist.
Research references
- Retinalamin retinal peptide bioregulator in retinal dystrophy: clinical studyPubMed
- Peptide bioregulators in ophthalmology: effects on retinal agingPubMed
- Retinalamin in age-related macular degeneration: neuroprotection of photoreceptorsPubMed
- Short peptide neuroprotection in retinal diseases: preclinical and clinical dataPubMed